Jeffrey S. Weber, MD, PhD

Where You Are:
Jeffrey S. Weber, MD, PhD

Senior Member

"As a tumor immunologist & immunotherapist, I focus on translational clinical trials including development of novel trials in melanoma based on my lab work."

Office  (813) 745-2007

Education And Training
  • Fellow, National Cancer Institute, 1990 - Surgery Branch, Tumor Immunology
  • Fellow, National Cancer Institute, 1988 - Surgery Branch, Tumor Immunology
  • Fellow, National Cancer Institute, 1986 - Medicine Branch
  • Resident, University of California, 1983 - Medicine
  • Intern, University of California, 1981 - Medicine
  • MD, New York University Medical Center, 1980
  • PhD, Rockefeller University, 1979 - Molecular Cell Biology


My research interests lie in the monitoring and characterization of T cell responses to vaccination in cancer patients, and in the establishment of in vitro models to facilitate the understanding of how immune modulating antibodies amplify T cell responses in patients. I am also interested in the mechanisms by which achieving autoimmunity induces regression of cancer.

  • Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. J Clin Oncol. 2014 Nov;32(33):3697-3704. Pubmedid: 25287827.
  • Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol. 2014 Nov;25(11):2277-2284. Pubmedid: 25210016.
  • McDermott D, Lebbé C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA, Balch CM. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014 Oct;40(9):1056-1064. Pubmedid: 25060490.
  • Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep;384(9948):1109-1117. Pubmedid: 25034862.
  • Chung B, Stuge TB, Murad JP, Beilhack G, Andersen E, Armstrong BD, Weber JS, Lee PP. Antigen-Specific Inhibition of High-Avidity T Cell Target Lysis by Low-Avidity T Cells via Trogocytosis. Cell Rep. 2014 Aug;8(3):871-882. Pubmedid: 25088413.
  • Weber JS. At the bedside: adoptive cell therapy for melanoma-clinical development. J Leukoc Biol. 2014 Jun;95(6):875-882. Pubmedid: 24732024.
  • Smalley KS, Weber JS. Up close and personal: the challenges of precision medicine in melanoma. J Natl Cancer Inst. 2014 Feb;106(2):djt443. Pubmedid: 24511111.
  • Ding L, Kim M, Kanchi KL, Dees ND, Lu C, Griffith M, Fenstermacher D, Sung H, Miller CA, Goetz B, Wendl MC, Griffith O, Cornelius LA, Linette GP, McMichael JF, Sondak VK, Fields RC, Ley TJ, Mulé JJ, Wilson RK, Weber JS. Clonal architectures and driver mutations in metastatic melanomas. PLoS One. 2014;9(11):e111153. Pubmedid: 25393105.
  • Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec;31(34):4311-4318. Pubmedid: 24145345. Pmcid: PMC3837092.
  • Radvanyi L, Pilon-Thomas S, Peng W, Sarnaik A, Mulé JJ, Weber J, Hwu P. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter. Clin Cancer Res. 2013 Oct;19(19):5541. Pubmedid: 24048330. Pmcid: PMC3823378.
  • Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep;31(26):3182-3190. Pubmedid: 23775962.
  • Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013 Sep;8(4):e60031. Pubmedid: 23560068. Pmcid: PMC3613355.
  • Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013 Aug;24(8):2174-2180. Pubmedid: 23666915. Pmcid: PMC4081656.
  • Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013 Aug. Pubmedid: 23963286.
  • Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 Jul;31(14):1767-1774. Pubmedid: 23569304.
  • Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul;369(2):134-144. Pubmedid: 23724846. Pmcid: PMC4126516.
  • Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013 Jun;119(9):1675-1682. Pubmedid: 23400564.
  • Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber J. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013 Jun;19(14):3977-3986. Pubmedid: 23741070.
  • Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013 Jun;18(6):733-743. Pubmedid: 23774827. Pmcid: PMC4063401.
  • Smalley KS, Weber JS. Taming the wild-types: targeting PAK1 in melanomas that lack BRAF mutations. J Natl Cancer Inst. 2013 Jun;105(9):591-592. Pubmedid: 23535072.
  • Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One. 2013 May;7(11):e48787. Pubmedid: 23226204. Pmcid: PMC3511501.
  • Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthy S, Wolchok JD. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 2013 May;13:7. Pubmedid: 23833564. Pmcid: PMC3700777.
  • Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med. 2013 Apr;10:146. Pubmedid: 22788688. Pmcid: PMC3527361.
  • Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. Sci Rep. 2013 Mar;2:765. Pubmedid: 23097687. Pmcid: PMC3479449.
  • Gibney GT, Weber JS. Expanding targeted therapy to NRAS-mutated melanoma. Lancet Oncol. 2013 Mar;14(3):186-188. Pubmedid: 23414591.
  • Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov;367(18):1694-1703. Pubmedid: 23020132. Pmcid: PMC3549295.
  • Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 2012 Nov;72(21):5483-5493. Pubmedid: 22942258.
  • Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012 Oct;35(8):615-620. Pubmedid: 22996367.
  • Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol. 2012 Sep;19(9):2932-2936. Pubmedid: 22350605.
  • Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012 Sep;23(9):2335-2341. Pubmedid: 22317769.
  • June C, Rosenberg SA, Sadelain M, Weber JS. T-cell therapy at the threshold. Nat Biotechnol. 2012 Jul;30(7):611-614. Pubmedid: 22781680.
  • Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012 Jul;30(21):2691-2697. Pubmedid: 22614989.
  • Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012 May;18(9):2502-2514. Pubmedid: 22351686. Pmcid: PMC3398738.
  • Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb;366(8):707-714. Pubmedid: 22356324. Pmcid: PMC3724515.
  • Thompson JA, Hamid O, Minor D, Amin A, Ron IG, Ridolfi R, Assi H, Berman D, Siegel J, Weber JS. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother. 2012 Jan;35(1):73-77. Pubmedid: 22130164.
  • Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012 Jan;106(1):85-91. Pubmedid: 22127285. Pmcid: PMC3251861.
  • Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother. 2012 Jan;35(1):89-97. Pubmedid: 22130166.
  • Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012 Jan;30(1):34-41. Pubmedid: 22124101.
  • Chang GY, Kohrt HE, Stuge TB, Schwartz EJ, Weber JS, Lee PP. Cytotoxic T lymphocyte responses against melanocytes and melanoma. J Transl Med. 2011 Dec;9(1):122. Pubmedid: 21794122. Pmcid: PMC3158754.
  • Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec;17(24):7765-7775. Pubmedid: 21994418. Pmcid: PMC3972922.
  • Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 2011 Dec;21(6):530-534. Pubmedid: 22051508.
  • Del Vecchio M, Mortarini R, Tragni G, Di Guardo L, Bersani I, Di Tolla G, Agustoni F, Colonna V, Weber JS, Anichini A. T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma. J Clin Oncol. 2011 Nov;29(32):e783-e788. Pubmedid: 21990398.
  • Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother. 2011 Sep;34(7):556-567. Pubmedid: 21760528. Pmcid: PMC3709852.
  • Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011 Aug;29(22):3044-3049. Pubmedid: 21709192.
  • Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun;364(26):2517-2526. Pubmedid: 21639810.
  • Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011 Jun;29(3):489-498. Pubmedid: 20082117.
  • Ribas A, Weber JS, Chmielowski B, Comin-Anduix B, Lu D, Douek M, Ragavendra N, Raman S, Seja E, Rosario D, Miles S, Diamond DC, Qiu Z, Obrocea M, Bot A. Intra-Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial. Clin Cancer Res. 2011 May;17(9):2987-2996. Pubmedid: 21385924.
  • Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C. White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy. Clin Cancer Res. 2011 Apr;17(7):1664-1673. Pubmedid: 21325070.
  • Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother. 2011 Apr;34(3):236-250. Pubmedid: 21389874. Pmcid: PMC3063939.
  • Weber J. Immunotherapy for melanoma. Curr Opin Oncol. 2011 Mar;23(2):163-169. Pubmedid: 21192262.
  • Melis M, Weber JM, McLoughlin JM, Siegel EM, Hoffe S, Shridhar R, Turaga KK, Dittrick G, Dean EM, Karl RC, Meredith KL. An elevated body mass index does not reduce survival after esophagectomy for cancer. Ann Surg Oncol. 2011 Mar;18(3):824-831. Pubmedid: 20865331.
  • Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin M, Weber JS. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011 Feb;17(4):896-906. Pubmedid: 21106722. Pmcid: PMC3041838.
  • Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 2011 Jan;10:9. Pubmedid: 20957980. Pmcid: PMC2964017.
  • Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2011 Jan;10:11. Pubmedid: 21090563. Pmcid: PMC2999944.
  • DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer. 2010 Nov;103(10):1548-1553. Pubmedid: 20924376. Pmcid: PMC2990578.
  • Hales RK, Banchereau J, Ribas A, Tarhini AA, Weber JS, Fox BA, Drake CG. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol. 2010 Oct;21(10):1944-1951. Pubmedid: 20237004.
  • Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010 Oct;37(5):430-439. Pubmedid: 21074057.
  • Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug;363(8):711-723. Pubmedid: 20525992. Pmcid: PMC3549297.
  • Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug;116(15):3683-3691. Pubmedid: 20564083.
  • Weber JS. From the guest editor: introduction for immunotherapy of cancer. Cancer J. 2010 July;16(4):294. Pubmedid: 20693838.
  • Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, Amatruda TT, Hersh E, Richards J, Weber JS, Hoon DS. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010 Apr;16(8):2402-2408. Pubmedid: 20371696. Pmcid: PMC2855775.
  • Rüttinger D, Winter H, van den Engel NK, Hatz R, Jauch KW, Fox BA, Weber JS. Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference. Oncologist. 2010;15(1):112-118. Pubmedid: 20061401. Pmcid: PMC3227889.
  • Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009 Dec;21(9):1065-1077. Pubmedid: 19651643. Pmcid: PMC2731790.
  • Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec;15(23):7412-7420. Pubmedid: 19934295.
  • O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol. 2009 Dec;27(36):6207-6212. Pubmedid: 19917850.
  • Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-induced hypophysitis: MR Imaging Findings. AJNR Am J Neuroradiol. 2009 Oct;30(9):1751-1753. Pubmedid: 19474123.
  • Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, Marshall E, Wagner S. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer. 2009 Sep;115(17):3944-3954. Pubmedid: 19536884.
  • Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009 Sep;15(17):5591-5598. Pubmedid: 19671877.
  • Zager JS, Weber JS. Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios - part II. Cancer Control. 2009 Jul;16(3):196-197. Pubmedid: 19556959.
  • Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol. 2009 May;24(5):643-650. Pubmedid: 19283671.
  • Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009 May;58(5):823-830. Pubmedid: 19198837.
  • Phan GQ, Weber JS, Sondak VK. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol. 2009 Jan;15(11):3014-3021. Pubmedid: 18716842.
  • Weber JS. Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma. J Invest Dermatol. 2008 Dec;128(12):2750-2752. Pubmedid: 18997841.
  • Weber J, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma. J Clin Oncol. 2008 Dec;26(36):5950-5956. Pubmedid: 19018089.
  • McLoughlin J, Melis M, Siegel E, Dean E, Weber J, Chern J, Elliott M, Kelley S, Karl R. Are patients with esophageal cancer who become PET negative after neoadjuvantchemoradiation free of cancer. J Am Coll Surg. 2008 May;206(5):879-886. Pubmedid: 18471715.
  • Thompson J, Curti B, Redman B, Bhatia S, Weber J, Agarwala S, SieversEL, Hughes S, Devries T, Hausman D. Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanom and Renal Cell Carcinoma. J Clin Oncol. 2008 Apr; 26(12):2034-2039. Pubmedid: 18347008.
  • Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother. 2008 Feb;31(2):215-223. Pubmedid: 18481391.
  • Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist. 2008;13 Suppl 4:16-25. Pubmedid: 19001147.
  • Weber J. Introduction. Immune-modulating antibodies. Oncologist. 2008;13 Suppl 4:1. Pubmedid: 19001144.
  • Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, Weber JS. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007 Oct;19(10):1223-1234. Pubmedid: 17898045.
  • Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007 Jul;12(7):864-872. Pubmedid: 17673617.
  • Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B. Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res. 2007 Jun;13(11):3312-3319. Pubmedid: 17545537.
  • Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007 May;4(5):e176. Pubmedid: 17488182. Pmcid: PMC1865558.
  • Hamid O, Solomon J, Scotland R, Garcia M, Sian S, Ye W, Groshen S, Weber JS. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res. 2007 Jan;13(1):215-222. Pubmedid: 17200357.
  • Brinkman J, Hughes S, Stone P, Caffrey A, Muderspach L, Roman L, Weber JS, Kast W. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers. 2007;23(4):337-352. Pubmedid: 17627067. Pmcid: PMC3851105.
  • Weber JS. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res. 2006 Oct;16(5):379-383. Pubmedid: 17013086.
  • Chen DS, Soen Y, Stuge TB, Lee PP, Weber JS, Brown Pp, Davis MM. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med. 2006 May;2(10):e265. Pubmedid: 16162034. Pmcid: PMC1216330.
  • Koh YT, Higgins SA, Weber JS, Kast WM. Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med. 2006;4:42. Pubmedid: 17059610. Pmcid: PMC1630705.
  • Weber JS. Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients. Ann Surg Oncol. 2005 Dec;12(12):957-959. Pubmedid: 16244797.
  • Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res. 2005 Feb;11(3):1237-1246. Pubmedid: 15709194.
  • Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005 Feb;23(4):741-750. Pubmedid: 15613700.
  • Lewis K, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, BaronA, Russ P, Gonzalez R. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest. 2005;23(4):303-308. Pubmedid: 16100942.
  • Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 2004 Nov;1(2):e28-e28. Pubmedid: 15578105.
  • Koya RC, Weber JS, Kasahara N, Lau R, Villacres MC, Levine AM, Stripecke R. Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro. Hum Gene Ther. 2004 Aug;15(8):733-748. Pubmedid: 15319031.
  • Wong R, Lau R, Chang J, Kuus-Reichel T, Brichard V, Bruck C, Weber J. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res. 2004 Aug;10(15):5004-5013. Pubmedid: 15297401.
  • Xu T, Shu C, Purdom E, Dang D, Ilsley D, Guo Y, Weber J, Holmes S, LeePP. Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res. 2004 May;64(10):3661-3667. Pubmedid: 15150126.
  • Talebi T, Weber JS. Peptide vaccine trials for melanoma: preclinical background and clinical results. Semin Cancer Biol. 2003 Dec;13(6):431-438. Pubmedid: 15001162.
  • Rubio V, Stuge T, Singh N, Betts M, Weber J, Roederer M, Lee P. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003 Nov;9(11):1377-1382. Pubmedid: 14528297.
  • Tagawa S, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, HickingbottomB, Smith J, Johnson D, Weber J. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003 Jul;98(1):144-154. Pubmedid: 12833467.
  • Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res. 2003 Apr;9(4):1301-1312. Pubmedid: 12684398.
  • Aparicio A, Eads C, Leong L, Laird P, Newman E, Synold T, Baker S, Zhao M, Weber J. Phase I trial of continuous infusion 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol. 2003 Mar;51(3):231-239. Pubmedid: 12655442.
  • Silverman M, Hedley M, Petry K, Weber J. Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. J Low Genit Tract Dis. 2002 Oct;6(4):206-211. Pubmedid: 17051023.
  • Pullarkat V, Lau R, Lee S, Bender J, Weber J. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods. 2002 Sep;267(2):173-183. Pubmedid: 12165439.
  • Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, II Smith W, Dutcher P, Gollob J, Longmate J, Johnson D. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002 Apr;128(4):214-218. Pubmedid: 11935312.
  • Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs. 2002 Apr;3(4):627-633. Pubmedid: 12090735.
  • Yu C, Chen J, Apuzzo M, O'Day S, Giannotta S, Weber J, Petrovich Z. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys. 2002 Apr;52(5):1277-1287. Pubmedid: 11955740.
  • Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol. 2001 Sep;19(18):3836-3847. Pubmedid: 11559721.
  • Margolin K, Longmate J, Synold T, Gandara D, Weber J, Gonzalez R, Johansen M, Newman R, Baratta T, Doroshow J. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs. 2001 Aug;19(4):335-340. Pubmedid: 11561695.
  • Atkins M, Redman B, Mier J, Gollob J, Weber J, Sosman J, MacPherson B, Plasse T. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin Cancer Res. 2001 Mar;7(3):486-492. Pubmedid: 11297238.
  • Weber J, Mule J. How much help does a vaccine-induced T-cell response need. J Clin Invest. 2001 Mar;107(5):553-554. Pubmedid: 11238555.
  • Weber J, Aparicio A. Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol. 2001 Mar;13(2):124-128. Pubmedid: 11224710.
  • Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback M, Weber J. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother (1997). 2001 Jan;24(1):66-78. Pubmedid: 11211150.
  • Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small L, Kast W, Fascio G, Marty V, Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000 Sep;6(9):3406-3416. Pubmedid: 10999722.
  • Noveroske JK, Weber JS, Justice MJ. The mutagenic action of N-ethyl-N-nitrosourea in the mouse. Mamm Genome. 2000 Jul;11(7):478-483. Pubmedid: 10886009.
  • Justice MJ, Carpenter DA, Favor J, Neuhauser-Klaus A, Hrabé de Angelis M, Soewarto D, Moser A, Cordes S, Miller D, Chapman V, Weber JS, Rinchik EM, Hunsicker PR, Russell WL, Bode VC. Effects of ENU dosage on mouse strains. Mamm Genome. 2000 Jul;11(7):484-488. Pubmedid: 10886010.
  • Weber JS, Salinger A, Justice MJ. Optimal N-ethyl-N-nitrosourea (ENU) doses for inbred mouse strains. Genesis. 2000 Apr;26(4):230-233. Pubmedid: 10748459.
  • Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999 Jun;5(6):677-685. Pubmedid: 10371507.
  • Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber J. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol Immunother. 1999 Apr;48(1):9-21. Pubmedid: 10235484.
  • Kuniyoshi J, Kuniyoshi C, Lim A, Wang F, Bade E, Lau R, Thomas E, Weber J. Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells. Cell Immunol. 1999 Apr;193(1):48-58. Pubmedid: 10202112.
  • Justice MJ, Noveroske JK, Weber JS, Zheng B, Bradley A. Mouse ENU mutagenesis. Hum Mol Genet. 1999;8(10):1955-1963. Pubmedid: 10469849.
  • Johnson B, Culley D, Shah R, Weber J, Venzon D, Yang J, Linehan W, Rosenberg S. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol. 1998 Mar;159(3):718-722. Pubmedid: 9474133 .
  • Mulé JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, Rosenberg SA, Schall TJ. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996 Aug;7(13):1545-1553. Pubmedid: 8864755.
  • Mule J, Custer M, Averbook B, Yang J, Weber J, Goeddel D, Rosenberg S, Schall T. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996 Aug;7(13):1545-1553. Pubmedid: 8864755 .
  • Yang J, Topalian S, Schwartzentruber D, Parkinson D, Marincola F, Weber J, Seipp C, White D, Rosenberg S. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer. 1995 Aug;76(4):687-694. Pubmedid: 8625167 .
  • Heywood G, Rosenberg S, Weber J. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J Natl Cancer Inst. 1995 Jun;87(12):915-922. Pubmedid: 7666481 .
  • Guleria A, Yang J, Topalian S, Weber J, Parkinson D, MacFarlane M, White R, Steinberg S, White D, Einhorn J, et a. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol. 1994 Dec;12(12):2714-2722. Pubmedid: 7989949 .
  • Guleria AS, Yang JC, Topalian SL, Weber JS, Parkinson DR, MacFarlane MP, White RL, Steinberg SM, White DE, Einhorn JH. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol. 1994 Dec;12(12):2714-2722. Pubmedid: 7989949.
  • Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab. 1994 Oct;79(4):934-939. Pubmedid: 7962300.
  • Mastorakos G, Weber J, Magiakou M, Gunn H, Chrousos G. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab. 1994 Oct;79(4):934-939. Pubmedid: 7962300 .
  • Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother. 1994 Aug;39(2):105-116. Pubmedid: 7519125.
  • Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994 Aug;86(15):1159-1166. Pubmedid: 8028037.
  • Salgaller M, Weber J, Koenig S, Yannelli J, Rosenberg S. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother. 1994 Aug;39(2):105-116. Pubmedid: 7519125 .
  • Yang J, Topalian S, Parkinson D, Schwartzentruber D, Weber J, Ettinghausen S, White D, Steinberg S, Cole D, Kim H, et a. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994 Aug;12(8):1572-1576. Pubmedid: 8040669 .
  • Kim H, Rosenberg SA, Steinberg SM, Cole DJ, Weber JS. A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. J Immunother Emphasis Tumor Immunol. 1994 Jul;16(1):60-65. Pubmedid: 8081560.
  • Kim H, Rosenberg S, Steinberg S, Cole D, Weber J. A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. J Immunother Emphasis Tumor Immunol. 1994 Jul;16(1):60-65. Pubmedid: 8081560 .
  • Weber J, Gunn H, Yang J, Parkinson D, Topalian S, Schwartzentruber D, Ettinghausen S, Levitt D, Rosenberg S. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunother Emphasis Tumor Immunol. 1994 May;15(4):292-302. Pubmedid: 7520334 .
  • Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg S. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res. 1994 Apr;54(7):1766-1771. Pubmedid: 7511051 .
  • Rosenberg S, Yang J, Topalian S, Schwartzentruber D, Weber J, Parkinson D, Seipp C, Einhorn J, White D. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Jama. 1994 Mar;271(12):907-913. Pubmedid: 8120958 .
  • Cole D, Sanda M, Yang J, Schwartzentruber D, Weber J, Ettinghausen S, Pockaj B, Kim H, Levin R, Pogrebniak H, et a. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J Natl Cancer Inst. 1994 Jan;86(1):39-45. Pubmedid: 8271281 .
  • Mastorakos G, Chrousos G, Weber J. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993 Dec;77(6):1690-1694. Pubmedid: 8263159 .
  • Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993 Dec;77(6):1690-1694. Pubmedid: 8263159.
  • Rosenberg S, Anderson W, Blaese M, Hwu P, Yannelli J, Yang J, TopalianSL, Schwartzentruber D, Weber J, Ettinghausen S, et a. The development of gene therapy for the treatment of cancer. Ann Surg. 1993 Oct;218(4):455-463. Pubmedid: 8215637 .
  • Rosenberg SA, Anderson WF, Blaese M, Hwu P, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Ettinghausen SE. The development of gene therapy for the treatment of cancer. Ann Surg. 1993 Oct;218(4):455-463. Pubmedid: 8215637. Pmcid: PMC1242999.
  • Weber J, Yang J, Topalian S, Parkinson D, Schwartzentruber D, Ettinghausen S, Gunn H, Mixon A, Kim H, Cole D, et a. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993 Mar;11(3):499-506. Pubmedid: 7680375 .
  • Weber J, Yang J, Topalian S, Schwartzentruber D, White D, RosenbergSA. The use of interleukin-2 and lymphokine-activated killer cells for thetreatment of patients with non-Hodgkin's lymphoma. J Clin Oncol. 1992 Jan;10(1):33-40. Pubmedid: 1727923 .
  • Karpati R, Banks S, Malissen B, Rosenberg S, Sheard M, Weber J, HodesRJ. Phenotypic characterization of murine tumor-infiltrating T lymphocytes. J Immunol. 1991 Mar;146(6):2043-2051. Pubmedid: 1672340 .
  • Fox BA, Spiess PJ, Kasid A, Puri R, Mulé JJ, Weber JS, Rosenberg SA. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod. 1990 Oct;9(5):499-511. Pubmedid: 2174966.
  • Fox B, Spiess P, Kasid A, Puri R, Mule J, Weber J, Rosenberg S. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod. 1990 Oct;9(5):499-511. Pubmedid: 2174966 .
  • Weber J, Rosenberg S. Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. J Natl Cancer Inst. 1990 May;82(9):755-761. Pubmedid: 2109092 .
  • Weber JS, Rosenberg SA. Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. J Natl Cancer Inst. 1990 May;82(9):755-761. Pubmedid: 2109092.
  • Feltner D, Cooper M, Weber J, Israel M, Thiele C. Expression of class I histocompatibility antigens in neuroectodermal tumors is independent of the expression of a transfected neuroblastoma myc gene. J Immunol. 1989 Dec;143(12):4292-4299. Pubmedid: 2687378 .
  • Weber J, Rosenberg S. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 1988 Oct;48(20):5818-5824. Pubmedid: 3139284 .
  • Weber J, Jay G, Tanaka K, Rosenberg S. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J Exp Med. 1987 Dec;166(6):1716-1733. Pubmedid: 3500265 .
  • Weber JS, Jay G, Tanaka K, Rosenberg SA. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J Exp Med. 1987 Dec;166(6):1716-1733. Pubmedid: 3500265. Pmcid: PMC2188791.
  • Weber J, Blanchard J, Ginsberg H, Darnell JE J. Order of polyadenylic acid addition and splicing events in early adenovirusm RNA formation. J Virol. 1980 Jan;33(1):286-291. Pubmedid: 6245233 .
  • Weber J. Peptide vaccines for cancer. Cancer Invest. 2002 20(;20(2):208-221. Pubmedid: 11901542.
  • Koya R, Kasahara N, Favaro P, Lau R, Ta H, Weber J, Stripecke R. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother. 2003 Sept;26(5):451-460. Pubmedid: 12973034.
  • Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J. 15(3):169-173. Pubmedid: 19556898.
  • Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance?. Cancer J. 16(4):311-317. Pubmedid: 20693841. Pmcid: PMC4052949.
  • Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Jama. 271(12):907-913. Pubmedid: 8120958.
  • Chiong B, Wong R, Lee P, Delto J, Scotland R, Lau R, Weber J. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine. J Immunother. 27(5):368-379. Pubmedid: 15314545.
  • Wall R, Weber J, Gage Z, Darnell J. Production of viral mRNA in adenovirus- transformed cells by the post-transcriptional processing of heterogeneous nuclear RNA containing viral and cell sequences. J Virol. 1973 Jun;11(6):953-960. Pubmedid: 4736534 .
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions